Phase 3 Clinical Trials With Primary Completion Dates in February 2020

This is a list of Phase 3 trials with primary completion dates in February 2020 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
BYSIBeyondSpring Inc.2020-02-01Phase 3NCT02504489Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC
CHHLChina Holdings, Inc.2020-02-01Phase 3NCT02856126HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC
DBVTDBV Technologies S.A.2020-02-01Phase 3NCT03013517Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children
IPSEYIpsen S.A.2020-02-01Phase 3NCT02683941Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors
MCRBSeres Therapeutics, Inc.2020-02-01Phase 3NCT03183141ECOSPOR IV: An Open-Label Extension of Study SERES 012 Evaluating SER-109 in Subjects With Recurrent Clostridium Difficile Infection
MDLHMedical International Technology, Inc.2020-02-01Phase 3NCT04029545A Multicenter, Double-blind, Randomized, Controlled, Roll-over Retreatment Study of the Safety and Pain Associated With Injections of PN40082, RV001 With Topical Anesthetic or RV001 for Lip Augmentation
MNLOMenlo Therapeutics Inc.2020-02-01Phase 3NCT03546816Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
MYGNMyriad Genetics, Inc.2020-02-01Phase 3NCT02655016A Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
OCULOcular Therapeutix, Inc.2020-02-01Phase 3NCT04061044A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert
OCULOcular Therapeutix, Inc.2020-02-01Phase 3NCT04050865A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis
OMEROmeros Corporation2020-02-01Phase 3NCT03205995Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome
OSMTOsmotica Pharmaceuticals plc2020-02-01Phase 3NCT03319732A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS
ZGNXZogenix, Inc.2020-02-01Phase 3NCT03790137Treatment of Sunflower Syndrome With ZX008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4-25).